HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$40.22
Day range
$38.46 - $40.71
Year range
$23.15 - $40.71
Market cap
1.96B USD
Avg Volume
315.02K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 103.69M | 29.22% |
Operating expense | 39.78M | 11.95% |
Net income | -177.00K | -102.03% |
Net profit margin | -0.17 | -101.56% |
Earnings per share | 0.00 | -100.00% |
EBITDA | -6.37M | 14.65% |
Effective tax rate | 158.22% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 892.35M | -0.99% |
Total assets | 1.10B | 1.65% |
Total liabilities | 705.94M | -0.12% |
Total equity | 396.56M | — |
Shares outstanding | 50.53M | — |
Price to book | 5.12 | — |
Return on assets | -1.64% | — |
Return on capital | -2.16% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -177.00K | -102.03% |
Cash from operations | -4.46M | -121.09% |
Cash from investing | 5.25M | 734.30% |
Cash from financing | 1.87M | 842.42% |
Net change in cash | 10.48M | -68.03% |
Free cash flow | -7.26M | -129.48% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
493
